Walgreens Boots Alliance, Inc. vs Verona Pharma plc: SG&A Expense Trends

SG&A Expense Trends: Walgreens Boots Alliance vs. Verona Pharma

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding the financial dynamics of key players is crucial. Walgreens Boots Alliance, Inc., a giant in the retail pharmacy space, has consistently reported substantial Selling, General, and Administrative (SG&A) expenses, peaking at approximately $28 billion in 2024. This represents a steady increase of around 60% from 2014. In contrast, Verona Pharma plc, a smaller player in the pharmaceutical industry, has shown a more volatile trend. Their SG&A expenses surged by over 2,600% from 2014 to 2023, reaching nearly $50 million. This stark difference highlights the scale and operational strategies of these companies. While Walgreens' expenses reflect its expansive global operations, Verona's growth in expenses may indicate strategic investments in research and development. Notably, data for 2024 is missing for Verona, suggesting potential reporting delays or strategic shifts.